Related Experiment Video
Updated: Apr 15, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
Bibiana Bielekova1, Michael P McDermott2
1From The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY. bibi.bielekova@nih.gov.
No abstract available in PubMed .
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells